

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

August 2012
Volume 15, Number 8

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Cancer Drug Manual** – Revised: Capecitabine, Goserelin, Medroxyprogesterone; Updated BCCA Hazardous Drug List
- **Benefit Drug List** – Deleted: Dexrazoxane for Pediatric Patients with Relapsed CD22-Positive ALL on the COG Protocol ADVL04P2, Trastuzumab in Pediatric Patients with Osteogenic Sarcoma
- **List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts** – New: HNAVFUP; Revised: UBRAJCEF, BRAJCMF, BRAJDTFEC, BRAVEXE, UBRLA2, UBRLACEF, GICART, GICPART, UGIFIRINOX, GOCXCRT, HNAVFUP, UHNLACETR, LYPALL, SAVACM
- **Website Resources and Contact Information**

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patients Handouts are listed below.

Capecitabine Monograph:

- Updated *Dosing* section to include a case study where capecitabine was used in patients with a creatinine clearance of less than 30 mL/min, and in patients requiring dialysis

Goserelin Monograph:

- Updated *Parenteral Administration* table with the recommended site for subcutaneous injection (anterior abdominal wall below the navel line) as per current product monograph

Medroxyprogesterone (MPA) Monograph and Patient Handout:

- Underwent comprehensive review to ensure up-to-date information in each document
- Expert review was provided by Dr. Paul Hoskins (Medical Oncologist, Gynecology Systemic Group) and James Conklin (Pharmacist, Gynecology Tumour Group)

Monograph:

- Clarified central vs. peripheral mechanisms of action when used in breast and endometrial cancers
- Added information on carcinogenic, mutagenic and fertility risks under *Precautions* section
- Side Effects section:
 - Removed side effects associated with MPA injection or use in combination with estrogen from *Side Effects* table

CANCER DRUG MANUAL

- Added paragraphs on Cushingoid symptoms and cerebrovascular insufficiency following the *Side Effects* table
- Interactions section:
 - Removed theoretical interaction with rifampin from the *Interactions* table
 - Removed interaction with thyroid function test (not relevant when used without concurrent estrogen)
 - Added glucose tolerance, cortisol and hormone level tests to the *Interactions* table
 - Added information on theoretical cytochrome P450 interactions following the *Interactions* table

Patient Handout:

- Removed from *Side Effects* table those associated with MPA injection or use in combination with estrogen

UPDATED BCCA HAZARDOUS DRUG LIST

Effective 01 August 2012, the [BCCA Hazardous Drug List](#) has been updated to reflect the 2012 edition of the “National Institute of Occupational Safety (NIOSH) List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012”. The revised NIOSH Hazardous Drug (HD) List was published in June 2012, of which 169 drugs were reviewed. Select new drugs or existing drugs with new blackbox warnings issued from June 2007 to December 2009 were added to the revised list.

Key changes to the BCCA Hazardous Drug List include:

1. The NIOSH 2010 HD list has been replaced by the 2012 HD List.
2. The following benefit drugs have been removed from the BCCA HD List Addendum (as they have now been added to the NIOSH 2012 HD List):
 - Degarelix
 - Everolimus
 - Nilotinib
 - Pazopanib
 - Temsirolimus
3. The following benefit drug has been reclassified as “hazardous” by NIOSH and added to the NIOSH 2012 HD list:
 - Cabergoline
4. The following benefit drugs have been reclassified as “non-hazardous” by NIOSH and have been removed from the BCCA Hazardous Drug list:
 - Alemtuzumab
 - Interferon alpha 2a, 2b, n3

For further information about the revised HD lists, please review the official [NIOSH publication](#), the [BCCA Hazardous Drug List](#), and/or the BCCA Pharmacy Directive VI-80 Hazardous Drug List (*BCCA internal document*). To learn more about the BCCA HD List review process, please see the [June 2011](#) issue of the Systemic Therapy Update.

BENEFIT DRUG LIST

DELETED PROGRAMS

The following programs have been deleted from the Benefit Drug List effective 01 August 2012 to reflect current practice:

- **Dexrazoxane** (class II) for pediatric patients with relapsed CD22-positive acute lymphoblastic leukemia on the COG protocol ADVL04P2
- **Trastuzumab** (class II) in pediatric patients with osteogenic sarcoma

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

NEW Protocols, PPPOs and Patient Handouts (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
HNNAVFUP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using CISplatin and Fluorouracil

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UBRAJCEF	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Revised protocol code names</i>	Adjuvant therapy for Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
BRAJCMF	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarified lab tests</i>	Adjuvant Therapy for High Risk Breast Cancer Using Cyclophosphamide (IV), Methotrexate and Fluorouracil
BRAJDTFEC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarified trastuzumab dosing under Treatment section</i>	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Trastuzumab, and Fluorouracil, Epirubicin and Cyclophosphamide
BRAVEXE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Deleted precaution on interactions with grapefruit and grapefruit juice</i>	Palliative Therapy for Advanced Breast Cancer Using Exemestane

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UBRLA2	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Corrected Fluorouracil dosing interval</i>	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, DOXOrubicin and Fluorouracil
UBRLACEF	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Revised protocol Code names</i>	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
GICART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarified capecitabine dosing regimen</i>	Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy
GICPART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarified capecitabine dosing regimen</i>	Combined Modality Therapy for Carcinoma of the Anal Canal using CISplatin, Capecitabine and Radiation Therapy
UGIFIRINOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Clarified Dose Modifications section</i>	Palliative Combination Chemotherapy for Metastatic Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Folinic Acid (Leucovorin)
GOCXCRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarified lab tests</i>	Treatment of High Risk Squamous Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma of the Cervix with Concurrent CISplatin and Radiation
HNAVFUP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Clarified treatment calendar</i>	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using CISplatin and Fluorouracil
UHNLACETRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarified observation and vital signs monitoring</i>	Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
LYPALL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Deleted interferon for use in myeloma</i>	Lymphoma Palliative Chemotherapy
SAVACM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Clarified hydration regimen under Treatment section</i>	Therapy For Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumor (PNET) and Rhabdomyosarcoma With Pelvic Primaries or Chemotherapy Induced Hematuria Using VinCRISline, DOXOrubicin and Cyclophosphamide. (SAVACM is Alternated with SAIME)

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 3028		sman3@bccancer.bc.ca
Provincial Systemic Therapy Program	604.877.707.5973		ldasilva2@bccancer.bc.ca
Communities Oncology Network (CON)	250.519.5501		jdenduyf@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 2638		nursinged@bccancer.bc.ca
Library/Cancer Information	888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 2623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Man, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Johanna Den Duyf, MA
 Caroline Lohrisch, MD

Beth Morrison, MLS
 Lindsay Schwartz, RN, MScA
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)